Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects

NCT01227824 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT01227824
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01227824 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Lead sponsor
ViiV Healthcare
Phase
Phase 3
Overall status
Completed
Start date
October 19, 2010
Completion date
December 27, 2016
Enrollment
828 (actual)
Sites
101

Conditions

As the registry lists them; a condition with its own page is linked.

infection, human immunodeficiency virus i